The most remarkable feature of the immune response is its ability to generate cells and antibodies specifically reactive with an enormous variety of foreign antigens while normally avoiding the production of autoreactive elements. An accumulating body of data demonstrates that a distinct lineage of B cells (1), the Ly-1 + B cell subset, does not display this feature, but rather is associated with the production ofautoreactive antibodies (2). We are unaware of autoimmune pathology directly demonstrated to be the result of an Ly-1 + B cell-Ig product; however, Ly-1+ B cell frequency is elevated in some autoimmune strains of mice (3). In addition to their association with autoreactive antibody, Ly-1 + B cells have been shown to have unique growth potential (1, 4); to produce most of the serum IgM found in normal, unimmunized animals (4); and the Ig repertoire of the subset may be restricted (4, 5). These findings imply that this subset has a role in normal physiology, and perhaps autoimmune pathology. A B cell subset has been identified in humans that bears the homologous marker Leu-1/T1 (CD5) (6). A similar functional role for CD5+ B cells in man has been proposed (7); human CD5+ B cells have been shown to produce autoreactive antibody (8, 9) and to be present at elevated frequency in rheumatoid arthritis (10).Normal mice produce antibodies that are reactive with protease-treated autologous erythrocytes (BrMRBC) 1 (11) ; cells producing such antibodies are present in unimmunized mice at very high frequencies, as first demonstrated by Cunningham (12) . We and others (13)(14)(15) have shown that at least some anti-BrMRBC plaqueforming cells (PFC) recognize the polar headgroup of the common membrane phospholipid, phosphatidyl choline (PtC). Most splenic anti-BrMRBC PFC have been